Enorama Pharma AB (ERMA) Stock Statistics & Valuation Metrics

Enorama Pharma AB has a market cap or net worth of kr208.85M. The enterprise value is kr179.91M.

Enorama Pharma AB has 74,588,684 shares outstanding. The number of shares has decreased by -2.65% in one year.

Enorama Pharma AB’s return on equity (ROE) is -5.61 and return on invested capital (ROIC) is -608.93%.

The current PE Ratio of Enorama Pharma AB is ―. Enorama Pharma AB’s PEG ratio is 0.11.

In the last 12 months, Enorama Pharma AB had revenue of 15.77M and earned -43.81M in profits. Earnings per share was -0.83.

In the last 12 months, operating cash flow was -46.36M and capital expenditures 0.00, giving a free cash flow of -46.36M billion.

Enorama Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Enorama Pharma AB upcoming earnings date is Feb 18, 2026, TBA (Confirmed).

Enorama Pharma AB as a current ratio of 1.87, with Debt / Equity ratio of 0.00%

In the past 12 months, Enorama Pharma AB has paid 0.00 in taxes.

Enorama Pharma AB EV to EBITDA ratio is -8.63, with an EV/FCF ratio of -4.93.

Enorama Pharma AB has kr2.52M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr2.52M billion.

Gross margin is -65.68%, with operating margin of -301.34%, and net profit margin of -277.82%.

The average price target for Enorama Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―